Ametek (AME) Q3 2025 10-Q Quarterly Report
Filed: Oct 30, 2025Period ending Sep 30, 2025
Health Care
Industrial Instruments For Measurement, Display, and ControlSEC EDGAR Ametek (AME) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 30, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Ametek Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1,892.6M Q3 2025, up $184.0M or 10.8% YoY from $1,708.6M in Q3 2024
- • Operating margin 25.8% Q3 2025 vs 26.1% Q3 2024; segment margin 27.3% vs 27.5% YoY, with 130bps acquisition dilution
- • Best segment EMG: sales $646.3M (+12.6%), operating margin 25.4% vs 22.9% YoY; worst segment EIG margin decline to 28.3% from 29.9%
- • Cash from operations $1,217.5M for 9M 2025, down 4.8% YoY; paid $933.2M for acquisitions; increased debt to $2,464.2M from $2,079.7M
- • Near-term risk from US tariffs and trade restrictions; management proactive on pricing and supply chain; guidance not updated explicitly
Risk Factors
- • Section 'risk_factors' was empty or not found.
Ametek Q3 2025 Quarterly FinancialsXBRL
Revenue
$1.9B
▲ +10.8% YoY▲ +6.4% QoQ
Net Income
$371M
▲ +9.2% YoY▲ +3.6% QoQ
Net Margin
19.6%
▼ -29bp YoY▼ -53bp QoQ
Source: XBRL data from Ametek Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Ametek
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.